IE
PMCB icon

Israel Englander’s PharmaCyte Biotech PMCB Stock Holding History

Israel Englander’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,018
Closed -$60K – 6932
2022
Q3 		$60K Buy
25,018
+7,499
+43% +$19K ﹤0.01% 6124
2022
Q2 		$40K Buy
+17,519
New +$38.3K ﹤0.01% 6272

Other funds holding PMCB

AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Israel Englander's PMCB Position: Q4 2022 in Review

Israel Englander sold out of PharmaCyte Biotech (PMCB) in Q4 2022, closing a stake of 25,018 shares — an estimated $60K sold.

Israel Englander first reported a position in PMCB in Q2 2022 and held it in 2 quarters. The position peaked at $60K in Q3 2022. 30 funds tracked by Wall St. Rank hold PMCB as of Q4 2022.

  • Israel Englander reported no remaining PharmaCyte Biotech position as of Q4 2022 after selling out during the quarter.
  • Israel Englander sold 25,018 PharmaCyte Biotech shares in Q4 2022, an estimated $60K.
  • Israel Englander first reported a position in PharmaCyte Biotech in Q2 2022 and held it in 2 quarters.
  • Israel Englander's PharmaCyte Biotech position peaked at $60K in Q3 2022.
  • 30 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.